Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 29 out of 100. Genetics

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

A Doença de Alzheimer (DA) é uma das condições neurodegenerativas mais prevalentes do Sistema Nervoso Central (SNC), caracterizada pelo acúmulo anormal de placas beta-amilóide (Aβ) e emaranhados neurofibrilares, levando à degeneração neuronal e ao comprometimento progressivo das funções cognitivas. Esse processo manifesta-se por dificuldades de memória, reconhecimento de pessoas e espaços, além de prejuízos na realização de atividades diárias. Com previsão de atingir cerca de 150 milhões de pessoas até 2050, a DA representa um desafio crescente para a saúde pública no Brasil e no mundo. Diante desse cenário, este estudo tem como objetivo compreender a eficácia de novas abordagens terapêuticas para a DA, avaliando seu impacto nos mecanismos fisiopatológicos da doença. Para isso, foi realizada uma revisão integrativa da literatura com 38 artigos publicados entre 2020 e 2025, selecionados nas bases de dados Scientific Library Online (Scielo), PubMed e Biblioteca Virtual de Saúde (BVS). Os dados analisados apontam que os pacientes com DA apresentam déficit de acetilcolina e de seus receptores, justificando o uso de inibidores da colinesterase, como Rivastigmina, Donepezil e Galantamina, com o intuito de prolongar a meia-vida desse neurotransmissor. No entanto, novas terapias emergem como alternativas promissoras, com foco em diferentes aspectos fisiopatológicos da DA. Dentre essas abordagens, destacam-se as terapias anti-amiloide, anti-tau, anti-neuroinflamatórias e terapias genéticas, como aquelas associadas à apoproteína E (APOE). Essas estratégias inovadoras são fundamentais para pacientes que não respondem adequadamente aos tratamentos convencionais, evidenciando a necessidade de aprofundar estudos e ampliar as possibilidades terapêuticas para retardar a progressão da doença.

What this study adds

Evidence grade: Low

This integrative review covers existing cholinesterase inhibitors such as rivastigmine, donepezil, and galantamine, and notes that new therapies are emerging as promising alternatives targeting different aspects of Alzheimer disease. It is a review of published literature and reports no new treatment, cure, or prevention results of its own.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Sampaio, C. A., Lima, L. C., Gonçalves, M. F. D. S., Silva, M. C. F., da Silva, B. M. d. S. M., Coelho, D. C. G., et al. (2025). Perspectivas futuras do tratamento farmacológico para doença de Alzheimer: uma revisão integrativa. Revista JRG de Estudos Acadêmicos. https://doi.org/10.55892/jrg.v8i18.2025

Vancouver

Sampaio CA, Lima LC, Gonçalves MFDS, Silva MCF, da Silva BMdSM, Coelho DCG, et al. Perspectivas futuras do tratamento farmacológico para doença de Alzheimer: uma revisão integrativa. Revista JRG de Estudos Acadêmicos. 2025. doi:10.55892/jrg.v8i18.2025.

BibTeX

@article{sampaio2025-f5f86458,
  author  = {Sampaio, Camille Almeida and Lima, Lívia Cardoso and Gonçalves, Maria Fernanda Dos Santos and Silva, Maria Cecília Farias and da Silva, Bruno Melo da Silva Melo and Coelho, Débora Costa Gomes and Farias, Any Eduarda Nanes de Oliveira and de Carvalho, Fábio Luiz Oliveira and others},
  title   = {{Perspectivas futuras do tratamento farmacológico para doença de Alzheimer: uma revisão integrativa}},
  journal = {Revista JRG de Estudos Acadêmicos},
  year    = {2025},
  doi     = {10.55892/jrg.v8i18.2025},
  url     = {https://doi.org/10.55892/jrg.v8i18.2025}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This integrative review covers existing cholinesterase inhibitors such as rivastigmine, donepezil, and galantamine, and notes that new therapies are emerging as promising alternatives targeting different aspects of Alzheimer disease. It is a review of published literature and reports no new treatment, cure, or prevention results of its own.

Study details

How this study scored 29/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 0 of 4; Institution's track record 0 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 1 of 2; Free to read 2 of 2. Total 29 of 100.29 of 100 points earned71 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Revista JRG de Estudos Acadêmicos)
Journal's citation record 0 / 4 Revista JRG de Estudos Acadêmicos: journal h-index 5 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 2 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.7 citations a year over 3 year(s) since 2025
Impact for its field and year 2 / 6 Cited 1.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 0 / 4 Last-listed author Felipe Mendes de Andrade de Carvalho: h-index 4 (OpenAlex, whole career)
Institution's track record 0 / 3 Universidade Federal de Sergipe: institution h-index 196 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 2 / 2 Free to read
Total 29 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Genetics from nearby years

Also in Genetics

198 studies in the library are filed under Genetics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Genetics hub.

Similar studies

More on Genetics

See all studies in Genetics →